BioCentury This Week

Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors

• BioCentury • Season 6 • Episode 329

Share episode

Novartis’ biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the $12 billion deal for Avidity in the context of Novartis’ recent acquisitions and the antibody-oligonucleotide conjugate platform it is gaining.
The team dives into RNA versus DNA modalities, noting antisense and siRNA approaches appear to be gaining traction with major pharmas as traditional gene therapy and gene editing approaches hit rocky times. Still, they note hopeful progress among base editing therapies given the promising early track records of over a dozen base editors in the clinic. They also discuss BioCentury’s conversation with base editing inventor David Liu; Alkermes’ $2.1 billion acquisition of Avadel; and β-catenin data from Parabilis. This episode of BioCentury This Week is sponsored by Evotec.

View full story: https://www.biocentury.com/article/657412

#AntibodyOligonucleotideConjugates #RNAtherapeutics #BaseEditing #MuscularDystrophy #WntPathway #BetaCatenin #Orexin2Receptor #PrecisionMedicine

00:01 - Sponsor Message: Evotec 
02:04 - 12th China Healthcare Summit
08:11 - Novartis' $12B Deal
16:58 - Alkermes M&A
20:01 - David Liu Base Editing
25:02 - Parabilis' Data

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text

[AI-generated transcript.]

Alanna Farro:

BioCentury This Week is brought to you by Evotec. Evotec is a life science company, pioneering drug discovery and development by integrating deep disease expertise, AI-driven innovation, and advanced technologies. Working across modalities, Evotec's, fully integrated R&D value chain and flexible partnering models accelerate the journey from concept to cure. A key area of focus is cell therapy, where Evotec leverages cutting-edge IPSC technology, manufacturing know-how, and translational capabilities to deliver scalable, off-the-shelf solutions for complex diseases. From discovery through GMP production, Evotec supports the development of cell-based therapies, advancing regenerative medicine and bringing transformative treatments closer to patients.

Jeff Cranmer:

Novartis is getting three late stage muscular dystrophy therapies via a $12 billion takeout in what is the Swiss pharma's biggest deal in a decade and more dealmaking, a busy week for M&A last week, Alkermes hopes to establish its commercial presence in narcolepsy via a $2.1 billion buy of Avadel and taking n-of-1 base editing therapies. Into broader populations. Takeaways from BioCentury's Conversation with David Liu of the Broad Institute of MIT and Harvard . Plus promising data sparks a clinical opportunity for paralysis. I'm Jeff Cranmer. This is the BioCentury's this week podcast. I'm one of the executive editors here at BioCentury, and joining me today are my colleagues.

Simone Fishburn:

Simone Fishburn, editor in chief.

Paul Bonanos:

Paul Bonanos, director of Biopharma Intelligence.

Selina Koch:

Selina Koch, Executive editor.

Lauren Martz:

And Lauren Martz, executive Director of Biopharma Intelligence.

Jeff Cranmer:

All right, Simone. Uh, like me just off the plane from Shanghai, feeling a little, jet lag, but very, very energized. how was your week in Shanghai? Simone.

Simone Fishburn:

really pretty exciting. Okay. so much energy at this conference. I think we probably say that every time because I feel like, China Biotech only has sort of two levels, like highly active and super highly active. There's no kind of, you know, slow day there. but you know, I know there's, a podcast that we did, especially at the meeting. to wrap it up. And I really encourage people to listen to that one. And I'm gonna tell you some of the highlights for me of that meeting, that might tell you why you should go and listen to that one. obviously, you know, the week kicked off with this big deal, between Innovent and Takeda, with a 1.2 billion upfront. And Paul, you did a great story on that last week. I think putting it as there. Second biggest ever. But I, I could even say, although there's a lot of buzz about it, nobody in China is surprised about this anymore. The China ecosystem has a lot of confidence in what they're doing in their ability to compete globally in their ability to take anything that requires an antibody and engineer the heck out of it and do it really fast and well and generate data and, Jeff, you might allude to this in a minute. The Hong Kong stock exchanges for biotech is doing remarkably well. So are sort of, I would say quite a lot of buzz there, and various threads that are coming out that we are seeing how that ecosystem is maturing. seeing a next generation of biotech leaders coming up who don't necessarily feel that they need to gain their chops outside of China, for example, in the U.S. there's a lot of going on domestically where they can hone their skills. That's just, you know, one of several things now that we'll tap into is, you know, RNA, the next frontier, what they've done for antibodies, can they do for RNA? So Jeff, what were your thoughts?

Jeff Cranmer:

Yeah, I mean, speed, like my trip started with, uh, a ride into town on the maglev train at 301 kilometers per hour. And I think that

Simone Fishburn:

Well, mine was terrible. I took like an hour and a half to go very little distance,

Jeff Cranmer:

you got the one New York cabbie, uh, in, in Shanghai. I, I actually had a, a terrifying. cab ride or two, I, I actually, uh, screamed in my cab as, uh, he, uh, launched his electric vehicle within one inch of another car that was attempting a, multi-point turn. And, uh, when we got out of the cab, I, I, I said, man, you're ready for F1? And, and he understood me and laughed. but yeah, I think it's just the speed, The ability to turn over things quickly, like back to cars. Literally every car in Shanghai is a brand new electric car. suffice to say, there was a McLaren parked in front of the hotel. but yeah, a lot of first time folks, we went out to, uh, the Zhangjiang life Sciences Park. And for me it was surprising to see so many Western companies with their incubators set up there. I think we saw Bayer, we saw a whole bunch, and indeed, uh, Western companies are all over the place. as our CEO just said on our editorial call or shared a picture rather, Shanghai's, tallest building illuminated in blue, with Pfizer's name written down the side. So, western companies, uh, are, are waking up. Lot of folks at our conference there for the first time wanted to see it with their own eyes, but even they, they, they're like, I'm gonna have to like, convince people in my home office that, this Shanghai thing is for real. And one way they could do that is pointing to what you said earlier, Simone, the, the Innovent deal. Uh, I just wanted to clarify when you said it was second biggest, uh, that's the second largest upfront payment in a licensing deal at 1.2 billion. That's just on the heels of the Pfizer 3SBio upfront payment that we saw earlier this year.

Selina Koch:

Jeff, when you started talking about speed and cars, I thought for sure you were gonna pivot to CAR Ts.

Jeff Cranmer:

Yes. Well, uh,

Selina Koch:

great precedent of Esobiotec showing like China speed through, through InVivo CAR T, um, early clinical development there.

Simone Fishburn:

Selina, it's interesting that you say that because, and I think we should stop 'cause we'll send people to the other pod. But that inside China is considered probably one of the seminal deals, like there are certain nodes on the pathway. I'm not sure that everybody in the West understood the significance of it, but the idea of a company in Europe deciding it's got only so much money and how's it gonna get data and going to China to do those early clinical trials. The ecosystem there like lords that and thinks that that is, that is the way things will go. So really good call out by you on that one. Yeah.

Jeff Cranmer:

Yeah, uh, I was, you know, uh, it's sort of like a Stockton to Malone thing. Uh, Selina, I was just sort of setting you up for your slam dunk there. I will say that, uh, JP, the CEO of Esobiotec, was a very, very popular person. At the meeting. And with that, look out for, BioCentury this week. live on tape from Shanghai. it's a good one. Uh, we had, the CEO of Duality. Uh, we had the CFO of a Akeso, and we had, one of the top guys, from, Charles River. on the podcast. all right, I'd like to bring in Paul now. Paul has been busy. He, he, wrote about Innovent, last week, uh, yesterday. He, uh, took a little break from, uh, playing baseball in the yard or watching football, whatever he gets up to down in, uh. Florida to, uh, write about Novartis, uh, Novartis getting three late stage RNA therapeutics for muscular dystrophies via a $12 billion acquisition of Avidity. Paul.

Paul Bonanos:

Yeah, so it's a big deal even for a company of Novartis's size. Uh, we've written about how, Vas Narasimhan, the CEO. He said he prefers smaller deals with, big potential. so presumably Novartis believes the assets it's getting from Avidity are, um, potential multi-billion dollar sellers. That's what Vas says. He's always looking for high value programs. and just to clarify, when we talk about getting assets, yes, Novartis is buying the whole company Avidity, but it's also planning a spin out. So we'll get to that in a second. Um, they're doing the deal to get three late stage programs all for different types of muscular dystrophy. They could all be on the market in the next few years. Uh, avidity had been lining up submissions for 2026. all three are antibody-oligonucleotide conjugates. We talk about ADCs antibody drug conjugates all the time. These have an oligo linked to an antibody for specific delivery into, Cell types or tissues. and in this case, all three have del in their names short for delpacibart, that's one component of the therapies. So Del-zota is for Duchenne muscular dystrophy, specifically for Exon 44 skipping, that has shown both biomarker and functional improvements in the clinic. And Avidity thinks it can submit for accelerated approval next quarter. There's Del-desiran, that's for myotonic dystrophy. Type one, DM1, and then there's Del-brax for, and this is a mouthful, fascioscapulohumeral muscular dystrophy. I hope I said that right. Uh, those latter two programs have both generated clinical data already more due by the second quarter of 2026, and um, they could go to regulators by year end next year.

Simone Fishburn:

Paul. So, you know, we're seeing a fair number of deals at Novartis. Some of them since Ronny Gal joined as. Chief Strategy Officer. and then this one in the antisense space sort of comes on the heels of they've got Leqvio right

Paul Bonanos:

That's via a very large deal with the medicines Co. Uh, to obtain the medicines co to acquire it in, I think 2019. And that's before Ronnie gal's time, but um, that was 9.7 billion. This is even bigger. Yes.

Simone Fishburn:

And they have one against Lp(a) Both of those are sort of in the cardiovascular space, it feels like this. modality is one that they're moving into, they're putting more money into. They obviously, feel that they've got good traction there. It's probably been commercially de-risked and maybe even scientifically de-risked or. If that's the right word. Um, so I don't know Selina, Lauren, how do you look at this technology in what Novartis is doing and maybe even other companies, do you think?

Selina Koch:

I was gonna

Simone Fishburn:

things to come.

Selina Koch:

yeah, I was gonna say we should bring it in Lauren, because she recently spoke to Tony Wood at GSK, they've really, they stopped their sort of AAV development, but they're kind of really doubling down on RNA modalities, so maybe she wants to talk about that.

Lauren Martz:

I think just the fact that we're seeing multiple large pharma companies exiting gene therapies or gene editing therapies, or at least deprioritizing some of these and, looking more into the oligos, the siRNAs, the, you know, uh, all of the RNA based modalities. I think that's just a testament to where this modality stands. You know, it's relatively de-risk. There are multiple programs on the market that, you know, commercially are relatively de-risked too. And you've also got the fact that, with a CRISPR based therapy for multiple indications, you're not actually seeing necessarily more knockdown of whatever the target is than you might see with an RNA therapy like this. it's opening the world of targets to something that you can't address right now with, with more of the traditional modalities. And it seems to have a more de-risked path than some of the even newer modalities, than, than what we have for potentially comparable efficacy and long term efficacy, just not one and done. yeah, I, I think more to, more to come from the pharmacist probably.

Selina Koch:

I think that comparison to gene editing is really interesting because there was a time, a moment in time where we're like, is gene editing just gonna supplant all of these RA modalities? And that just hasn't been the case at all.

Simone Fishburn:

I mean, I think we also have to give some credit to Alnylam who really did the heavy lifting on a lot of this. It was not a short journey, you know, one of the 20 year overnight success stories that we talk about. And they as a company have really dominated this space. And now there are other companies, obviously with products. Many of those, you know, came from that technology. And I think it's, we don't know yet whether gene editing is sort of just partway through its journey and gonna make it, there seems to be a, I dunno if I would call it cyclical, but certainly something like a sine wave going up and down there on, on gene therapies. But there are lots of reasons and there are people who, even in the heyday, which is just a few years ago, if Gene therapies were saying logically these antisense, even mRNA or you know, sRNA modalities carry lower risk and can do the same thing, there's still genetic medicines. They're still giving you the same kind of. Biological risk profile or lower biological risk profile, say small molecules ever will. So there's still a lot of the things that gene therapies do, these modalities do without perhaps some of the drawbacks.

Lauren Martz:

Tony Wood made a really interesting comment, which is that, you know, it's all about the durability. I don't think anyone expected these oligo therapies to be as durable. As they are when we set out, you know, RNA inherently is unstable, and so there's been a lot of work going into making these more stable and the fact that you could treat someone and have it last for six months makes a huge difference when you're comparing it with with other modalities as well.

Selina Koch:

We are at our Bio€quity conference. I talked to somebody at Alnylam about that who said it's really like they get trapped in the endozome but then they can like leak out slowly. So actually you turn that into to your advantage 'cause you get a bit of a time release and an extended activity, which is kind of neat and yeah, I don't think that was expected.

Paul Bonanos:

Simone, you mentioned the Novartis's experience with inclisiran Um, Leqvio, you know, in this modality, uh, you know, a lot of their deals are, into adjacent areas or other areas that they have experience with, and I thought I'd just mention also, This takeout, builds in musculoskeletal disease and, and you know, Novartis has had a lot of success in spinal muscular atrophy with that gene therapy. So this is adjacent to that. And Novartis also said it's complimentary to its neuro offerings. So, it's also adjacent to their MS drugs, and that's another area that they're building in with their deals. they've done deals, successive deals in, um, in kidney disease as well. they've done a really a, a whole lot of deals this year. This is the fourth pretty big one with Tourmaline, Regulus, and Anthos coming in last year was MorphoSys and a couple others as well. they've done a lot of deals since bringing in Ronny Gal as the gatekeeper, looking for high value products. So I just thought I'd mention all of that.

Jeff Cranmer:

And the, the Regulus deal brought in, earlier this year, a micro RNA, technology. Paul, um, there was a spin out in this deal.

Paul Bonanos:

Yes, I did mention that. so Avidity has some more preclinical programs that a couple of r sorry, mRNA, DEGRADERS for Cardiology indications. And those are going into the spin out, two rare cardio diseases, uh, associated with specific genetic causes. Avidity also has partnerships, two partnerships of note BMS, in cardiovascular indications and with Lilly in immunology. The deals also go into the spin out, and although Novartis gets the existing, AOC platform that's, um, antibody-oligonucleotide conjugate platform. That it makes the conjugates from, Avidity says the spin out will be able to iterate on it in, cardio disease to make technological modifications and maybe next generation products. So there's still some room to innovate there. And the, the chief programs officer at Avidity will become the CEO and the CEO will become the chair of the spin out. So retaining leadership continuity.

Jeff Cranmer:

All right, so the other big deal last week, Alkermes , Lauren, you just, wrote a story a couple of weeks ago about. Some really interesting narcolepsy data, from Alkermes as well as Takeda. both leaders in the space and now we see Alkermes, making a play for, Dublin Ireland based Avadel Pharmaceuticals. Tell us. a little bit about that.

Lauren Martz:

Thanks, Jeff. through this deal, they gain an approved drug for, some of the symptoms of narcolepsy, which is LUMRYZ (sodium oxybate). I think this deal really does two things for Alkermes, uh, maybe more. It gives them this commercial stage product, which may be complimentary to the internal programs that they have. It also gives them a commercial infrastructure in the sleep space, which is something that they didn't have. So the story that we wrote recently was about Phase II data for, um, the orexin 2 receptor agonists that Alkermes has. this is a new class in narcolepsy. they're slightly behind Takeda, which just released Phase III data for their program. as a new class, this works to replace the functionality that's lost specifically, in type 1 narcolepsy when these patients don't have the ligand for high enough expression ligand for this receptor. So these drugs are taken during the day to help people stay awake. Alkermes think they may have an advantage there as a once daily, once in the morning therapy. the sodium oxybate class of therapies is used at nighttime to help patients stay asleep. this particular one is also dosed once when patients go to bed, um, which, you know, may be a differentiation in that space. So there are these two programs in the narcolepsy space. Both could potentially have a dosing advantage. And, you know, as this company's preparing to advance this in this new class in the orexin 2 receptor agonist. they now are inheriting this, commercial team, commercial structure that, that's capable of, of working within the narcolepsy space.

Jeff Cranmer:

All right. We are gonna take a quick break and we'll come back to talk base editing.

Alanna Farro:

BioCentury This Week is brought to you by The 5th East-West Biopharma Summit in South Korea. An arc of innovation is emerging across Asia, and Western biopharma leaders are taking note-from cross-border deals to newcos. In March, 2026, The 5th BioCentury-BayHelix East-West BioPharma Summit visits South Korea for the first time. Meet the biopharma leaders putting Korea innovation on the global map. Learn why Korea has become a clinical trial in manufacturing hub. Discover if Korea is the next hotspot for NewCo formation. Plus, meet biopharma innovators from India to Singapore, to China and Japan. Register now at BioCenturyEastWest.com.

Jeff Cranmer:

And we're back. And I just wanted to give you a little shout out. Simone will be taking BioCentury's this week on the road to Cambridge, Massachusetts. So just wanted to give a shout out to our Boston listeners. we will be on the road, November 6th in the Boston, Cambridge area for K Blockbuster Night. I'm sure it will be golden. join us at Venture Cafe Cambridge and watch a live recording of the podcast with special guests joining Simone to discuss Korea biotech. Register for free at venturecafecambridge.org. or you can hit up our buddy Josh Berlin, our head of bd. On LinkedIn, you can hit me up as well to learn more and we hope to see you there. well, David Liu joined our colleague Danielle Golovin in conversation, recently and we ran a q and A in BioCentury and here with some takeaways. Uh, Selina.

Selina Koch:

thanks Jeff. I guess there were two things that really struck me about what he, um, said to Danielle. first is that his lab is working on a technology that could. Kind of overcome one of the big issues with base editing that makes it hard to, build a business on it. one of the great things about base editing is it goes after causal biology, pretty much by definition, It corrects a specific point mutation in a specific gene. And, often that's used for n-of-1 type bespoke therapies or n of a few, right? So super ultra rare indications, where the economics are hard to work out from a business kind of perspective. Um, so now they're working on something over there where you're still changing a specific, base, but instead of doing it in, in a gene that causes, you know, a specific disease or trying to do it in a gene that causes many diseases. So for example, there's a kind of wide range of diseases that are caused by premature stop codons. And so they now have a technology that can recognize this premature stop codon across many different genes, and therefore across many different rare diseases. And so once you start aggregating up these ultra rare diseases, maybe the economics can change. So I thought that was kind of interesting future direction of a technology.

Jeff Cranmer:

good stuff. Selina, what was your second takeaway? I.

Selina Koch:

So he mentioned in this interview that there are now 23 base editors in the clinic, um, which I had not realized there quite that many had advanced to the clinic. Um, so Danielle then went in a second story. She rounded all of those up. kind of assess their early track record. So, 13 of them have produced initial data and all 13 of them have made the intended change to the, the base, the base edit. And all of them have moved biomarkers in a direction that indicates clinical activity with, except for one case. mild manageable, safety. So when I think of like just early clinical track records for say, gene therapy, other new modalities, um, you'd be hard pressed to find one as looking as promising. I think.

Simone Fishburn:

So Selina, I think for many people he's a very known name, but some people probably know less about him. So just for context, He's founded some pretty big companies in this space, I imagine we expect to see more. You wanna just fill in anything on, uh, on the background of David Liu for our listeners?

Selina Koch:

Well, base editing that technology, led him to found a company called Beam Therapeutics, which is still a leader in that space. after, Base editing, which he invented around 2016 and 2019. there's a next generation technology called prime editing that can do some things. Base editing can't, that he also invented base editing can change something like 4 of the 12 possible base pair changes. Prime editing can hit them all and it can do some small in insertions and deletions. So that's an exciting development off of base editing. And that led to a company called Prime Medicine. which is so far the first and still only biotech to bring a prime editor into the clinic. that's an area to watch in the future. but then a lot of the, the work, those 23 trials we're talking about, a lot of those are still academic. cause as I said, the business proposition here is still an area that needs, some fleshing out.

Jeff Cranmer:

Yeah, he's uh, published more than 275 papers. Inventor on more than 110 issued U.S. patents and just a laundry list of, uh, prizes that he has won. and those companies, quite a few, uh, were watching quite closely nChroma Bio, Exo Therapeutics, Pairwise Plants, a few of his other companies as well. okay, uh, well, I'd like to bring it home by, uh, heading to the clinic. Parabilis, that's, uh, a company led by Mathai Mammen. had some pretty, promising data last week. And, Lauren, you took a little, uh, break out of your busy week to write about it. What did you learn?

Lauren Martz:

Yeah, so these were the first data that we, clinical data that we've seen for FOG-001, which was the β-catenin TCF interaction inhibitor, that Parabilis has been working on. The data we're, we're really encouraging. So at ESMO they presented data in desmoid tumors showing that of all the 10 patients that were, treated with this at first. They all had some tumor shrinkage, among the five in that trial who had at least two post baseline scans. And, you know, it takes some time for tumor shrinkage to occur here. four had partial responses, so that's an ORR of 80%. And you know, we've seen this for other mechanisms and other cancers, whatever. But I think this represents a potential really big breakthrough. Because of the target. So β-catenin is just one of those historically intractable cancer targets that everyone has been trying to solve for decades because it's mutated in a large percentage of cancer. So, you know, in a normal state, it's expression, it is sort of tightly controlled, it's regularly degraded and in cancers. Its expression, it can become more stabilized and it's a transcriptional regulator that when it's active, it can activate, the Wnt pathway genes, which can, contribute to cancer in multiple different downstream ways. So you're sort of, when the mutations occur, you're setting off this pathway. And the problem is that the interaction that activates these cancerous gene expressions. It doesn't have the types of binding grooves that you need for a small molecule to be effective and selective. And this isn't the only, function of this gene. So it needs to be done selectively, to not disrupt normal functions. So it's a very flat surface and we just haven't been able to target it with small molecules. So what Parabilis has done is they've used their α-helical stapled peptide technology to interact selectively in that groove. they also incorporate non-natural amino acids to give them more diversity in, the chemistry that they can use here to make that binding selective. And based on the data, it seems that, you know, we haven't seen this level of response. We haven't seen. This level of safety often when you have a non-selective inhibition of β-catenin, there could be lots of downstream safety issues as well. So it, it's a potential breakthrough. I think it's, it's very exciting data.

Selina Koch:

I think we saw, um, some bone safety issues with previous programs. Like you said, it's a complicated pathway with lots of different, um, complexes of proteins. And if you look at the diagram, it spins off in various directions and there's canonical and non-canonical. We've had disheveled inhibitor inhibitors, porcupine inhibitors, so on and so forth. Drizzled Wnt, but actually getting in the nucleus just at those, just at those transcription factors, driving the, you know, the, addicted, cancer, um. Does seem like progress and this is, uh, originally came out of Greg Verdine work right?

Lauren Martz:

It did. Yes, the, the stapled peptide technology.

Simone Fishburn:

Yeah, I was gonna say, so first of all, this pathway, I think by some distance, has the best names in it drizzled you know, really cool proteins all the way down to Porcupine. And there's a very nice, uh, graphic actually depicting this in the article there. that we put together. But yeah, this comes out of Greg Verdine's lab stapled peptides. I think it's a very interesting, twist. You know, Selina, we talk a lot about all of these other modalities. This is a small molecule modality that is, more engineering in the small molecule space and really trying to solve a problem. That hasn't been solved for a long time. So if they can do that at a technical level, at the same time as interrogating or accessing a pathway that's been resistant to, uh, to drug development, that would be a big win.

Lauren Martz:

Yeah. And so on Friday, they also showed that in the same trial, it wasn't limited to the efficacy, wasn't limited to the Desmoid tumors. Um, they also showed efficacy at the triple meeting in multiple other, Tumor types that don't have a particularly high mutational burden. So that's, that's where Parabilis is first taking this technology because at that stage, you know, there's a better chance that if you have a β-catenin mutation, that's the mutation that's driving the cancer. So, you know, you don't have to worry about additional mutations. Uh. Affecting the efficacy of targeting this pathway. but the company is looking to expand into more complex tumors, uh, specifically, uh, microsatellite stable colorectal cancer, I think in combinations, um, just based on some of the mechanisms of what happens when you do block this pathway.

Selina Koch:

Yeah. And it'll be interesting to see, um. if they're hypothesis about it, being able to kind of turn cold tumors warmer and, and synergize with PD-1, if that, you know, works out.

Jeff Cranmer:

Sounds good. Well, I'll drop a link. To all of these stories into the show notes. You can also find them at BioCenturypodcast.com. And if you like what you're hearing, uh, don't forget to like and subscribe. If you have a question for us drop us drop us a line, coming up on Wednesday, we'll release the. Podcast that we recorded in Shanghai on stage with some special guests. So look out for that. we'd like to thank Kendall Square Orchestra for providing the music to our podcasts.

Alanna Farro:

BioCentury would like to thank Evotec for supporting the BioCentury This Week podcast. To learn more about how Evotec can support your goals through pioneering drug discovery and development solutions, go to Evotec.com/innovation

Podcasts we love

Check out these other fine podcasts recommended by us, not an algorithm.